Agenus Inc.
3 Forbes Road
Lexington
Massachusetts
02421
United States
Tel: 781-721-3500
Fax: 781-938-6496
Website: http://www.antigenics.com/
Email: info@antigenics.com
430 articles about Agenus Inc.
-
Agenus to Participate at BTIG Biotechnology Conference
8/2/2022
Agenus today announced the Company will attend the BTIG Biotechnology Conference.
-
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
8/1/2022
Agenus Inc. today announced that the first patient has been dosed in the Phase 1 study of AGEN1571 in advanced solid tumors.
-
Agenus to Provide Corporate Update and Second Quarter 2022 Financial ReportConference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET
7/27/2022
Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will release its second quarter 2022 financial results before the market opens on Tuesday, August 9, 2022.
-
Agenus to Participate at William Blair’s Biotech Focus Conference
6/30/2022
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, will participate in a panel discussion on developing therapies for the next immuno-oncology targets at William Blair’s Biotech Focus Conference on Tuesday, July 12, 2022, at 4:10 PM EST.
-
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
6/21/2022
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hybrid webcast to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC).
-
GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissions
6/10/2022
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapies and adjuvants designed to activate the immune response to cancer and infections, today shared that partner GSK announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial evaluating their investigational RSV vaccine in adults aged 60 years and above.
-
Agenus Advances Portfolio with 6 Clinical Collaborations
5/31/2022
Agenus Inc. announced that it has entered into 3 new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations.
-
Agenus to Participate at Jefferies Healthcare Conference - May 25, 2022
5/25/2022
Agenus announced that Dr. Garo Armen, Chairman and CEO of Agenus and Dr. Steven O’Day, Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11:30 AM EST.
-
Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab
5/24/2022
Data to be Presented in Heavily Pretreated MSS-CRC Speed and Innovation Core to Development Strategy Reduction of 20% in 2022 Operating Costs.
-
Genentech's flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
-
Genentech (Roche) reported Wednesday that its Phase III SKYSCRAPER-01 trial failed to meet its co-primary endpoint of progression-free survival (PFS).
-
Agenus Corporate Update and First Quarter 2022 Financial Report
5/10/2022
Agenus Inc. provided a corporate update and reported financial results for the first quarter 2022.
-
Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
4/5/2022
Agenus Inc., an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, announced receipt of a $5M clinical milestone payment for AGEN2373.
-
Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.
-
Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
3/7/2022
Agenus and Targovax today announce that they have entered into a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines.
-
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
3/1/2022
Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies and adjuvants designed to activate immune response to cancers and infections, provided a corporate update and reported financial results for the fourth quarter and full year 2021.
-
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
2/15/2022
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its fourth quarter and full year 2021 financial results before the market opens on Tuesday, March 1, 2022.
-
Agenus to Participate at Upcoming Investor Conferences in January 2022
1/5/2022
Agenus, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that management will participate in the following upcoming investor conferences.
-
Balstilimab Plus Zalifrelimab Data Published in Journal of Clinical Oncology (JCO)
12/22/2021
Agenus (NASDAQ: AGEN), today announced the publication of results in the Journal of Clinical Oncology (JCO) from a global Phase 2 clinical study of balstilimab (Bal) plus zalifrelimab (Zal) in second-line (2L) recurrent/metastatic cervical cancer patients who had relapsed after treatment with platinum-based therapy.
-
Roche announced promising results from the Phase II CITYSCAPE study of tiragolumab plus Tecentriq compared to Tecentriq alone as a treatment for PD-L1-positive metastatic NSCLC.